Genetic analysis of a pedigree with hereditary coagulation factor XII deficiency.


Journal

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551

Informations de publication

Date de publication:
01 Sep 2021
Historique:
pubmed: 12 5 2021
medline: 27 11 2021
entrez: 11 5 2021
Statut: ppublish

Résumé

The aim of this study was to elucidate the molecular defects of a Chinese family with hereditary coagulation factor XII (FXII) deficiency. The FXII activity (FXII:C) and FXII antigen (FXII:Ag) levels were measured by clotting assay and ELISA, respectively. To identify mutations, the F12 gene sequencing was carried out. ClustalX-2.1-win and four online bioinformatics tools were applied to study the conservatism and harm of the mutation. The proband's FXII:C and FXII:Ag were 3 and 4%, respectively. Sequencing analysis revealed compound heterozygous mutations, including the deletion mutation (c.130delG) resulting in p.E26Sfs∗50 and the missense mutation (c.1561G>A) resulting in p.E502K. Bioinformatics indicated that mutations probably disrupt the function of the FXII protein. The c.130delG heterozygous deletion variation and the c.1561G>A heterozygous missense variation were responsible for the reduction of FXII:C in this family, of which c.130delG was first reported in the world.

Identifiants

pubmed: 33973893
doi: 10.1097/MBC.0000000000001044
pii: 00001721-202109000-00008
doi:

Substances chimiques

Factor XII 9001-30-3

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

406-410

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Références

Maruyama H, Brooks MB, Stablein A, Frye A. Factor XII deficiency is common in domestic cats and associated with two high frequency F12 mutations. Gene 2019; 706:6–12.
Kwon MJ, Kim HJ, Lee KO, Jung CW, Kim SH. Molecular genetic analysis of Korean patients with coagulation factor XII deficiency. Blood Coagul Fibrinolysis 2010; 21:308–312.
Tillman BF, Gruber A, McCarty OJT, Gailani D. Plasma contact factors as therapeutic targets. Blood Rev 2018; 32:433–448.
Shamanaev A, Emsley J, Gailani D. Proteolytic activity of contact factor zymogens. J Thromb Haemost 2021; 19:330–341.
Ivanov I, Verhamme IM, Sun MF, Mohammed B, Cheng Q, Matafonov A, et al. Protease activity in single-chain prekallikrein. Blood 2020; 135:558–567.
Renné T, Stavrou EX. Roles of factor XII in innate immunity. Front Immunol 2019; 10:2011.
Clark CC, Hofman ZLM, Sanrattana W, den Braven L, de Maat S, Maas C. The fibronectin type II domain of factor XII ensures zymogen quiescence. Thromb Haemost 2020; 120:400–411.
Zhang H, Liu S, Lin C, Luo S, Yang L, Jin Y, et al. Compound heterozygous mutations Glu502Lys and Met527Thr of the FXII gene in a patient with factor XII deficiency. Hematology 2019; 24:420–425.
Oguchi S, Ishii K, Moriki T, Takeshita E, Murata M, Ikeda Y, et al. Factor XII Shizuoka, a novel mutation (Ala392Thr) identified and characterized in a patient with congenital coagulation factor XII deficiency. Thromb Res 2005; 115:191–197.
Kanaji T, Kanaji S, Osaki K, Kuroiwa M, Sakaguchi M, Mihara K, et al. Identification and characterization of two novel mutations (Q421K and R123P) in congenital factor XII deficiency. Thromb Haemost 2001; 86:1409–1415.
Pauer HU, Renné T, Hemmerlein B, Legler T, Fritzlar S, Adham I, et al. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb Haemost 2004; 92:503–508.
Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202:271–281.
Li J, Guan X, Liu O, Wang X, Liu Y, Li H, et al. Changes in coagulation factor XII and its function during aortic arch surgery for acute aortic dissection – a prospective observational study. J Thorac Dis 2018; 10:4006–4016.
Citarella F, Fedele G, Roem D, Fantoni A, Hack CE. The second exon-encoded factor XII region is involved in the interaction of factor XII with factor XI and does not contribute to the binding site for negatively charged surfaces. Blood 1998; 92:4198–4206.
Baglia FA, Jameson BA, Walsh PN. Identification and characterization of a binding site for factor XIIa in the Apple 4 domain of coagulation factor XI. J Biol Chem 1993; 268:3838–3844.
Yang L, Wang Y, Zhou J, Cheng X, Hao X, Xie H, et al. Identification of genetic defects underlying FXII deficiency in four unrelated Chinese patients. Acta Haematol 2016; 135:238–240.
Jin P, Jiang W, Yan H, Liu L, Gu S, Wang X, et al. Novel mutations in congenital factor XII deficiency. Front Biosci (Landmark Ed) 2016; 21:419–429.

Auteurs

Haiyue Zhang (H)

Department of Clinical Laboratory, The First Hospital of Jiaxing & The Affiliated Hospital of Jiaxing University, Jiaxing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH